A contemporary concise review (2025) summarizing recent advances in interstitial lung disease (ILD), covering updated nomenclature, early detection, interstitial lung abnormalities (ILAs), multi-omic biomarkers, quantitative imaging, and novel antifibrotic/targeted therapies.
Key themes include: updated ILD classification aligning terminology with morphology and pathobiology; growing focus on early ILD detection and risk stratification in ILAs; emerging multi-omic biomarkers and quantitative imaging for prognostic stratification; and expanding antifibrotic/targeted therapies beyond IPF, with unmet needs in patient selection and treatment response.
As a narrative review, it does not provide primary data, pooled effect sizes, or systematic search methodology, limiting its evidentiary weight. Specific patient populations, sample sizes, and outcome data are not reported.
Multidisciplinary discussion remains the foundation of ILD care; clinicians should be aware of updated ILD nomenclature and the expanding therapeutic landscape beyond IPF, including novel antifibrotics and targeted agents. Early identification of high-risk ILA patients and integration of molecular/imaging biomarkers may help guide individualized management.
Explore related topics
